Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

2-Chloro-deoxyadenosine therapy for giant lymph node hyperplasia

L Bordeleau1, C Bredeson, S Markman

  • 1Division of Haematology, University of Ottawa, Ontario, Canada.

British Journal of Haematology
|November 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pre-Transplant Marital Status and Hematopoietic Cell Transplantation Outcomes

Current oncology (Toronto, Ont.)·2020
Same author

First-line therapy, autologous stem-cell transplantation, and post-transplantation maintenance in the management of newly diagnosed mantle cell lymphoma.

Current oncology (Toronto, Ont.)·2020
Same author

Evaluating dose-limiting toxicities of MDM2 inhibitors in patients with solid organ and hematologic malignancies: A systematic review of the literature.

Leukemia research·2019
Same author

Network geometry of evidence from randomised controlled trials addressing donor selection and source of haematopoietic progenitor cells used in allogeneic transplantation: a systematic scoping review.

Transfusion medicine (Oxford, England)·2018
Same author

Plerixafor for autologous stem-cell mobilization and transplantation for patients in Ontario.

Current oncology (Toronto, Ont.)·2016
Same author

Eltrombopag after allogeneic haematopoietic cell transplantation in a case of poor graft function and systematic review of the literature.

Transfusion medicine (Oxford, England)·2016

Giant lymph node hyperplasia (GLNH), a lymphoproliferative disorder, shows promise with 2-chloro-deoxyadenosine (2-CDA) therapy. This purine analogue offers a viable treatment option for unresectable or multifocal Castleman disease.

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Background:

  • Giant lymph node hyperplasia (GLNH), also known as Castleman disease, is a heterogeneous lymphoproliferative disorder with distinct histologic variants.
  • While localized forms are often surgically managed, effective treatments for multifocal disease remain elusive.

Observation:

  • Two cases of GLNH were treated with 2-chloro-deoxyadenosine (2-CDA), a purine analogue with known lymphocytic toxicity.
  • One patient with unresectable hyaline-vascular GLNH achieved a 9-month remission after 2-CDA and radiation therapy.
  • A second patient with disseminated plasma cell variant showed a partial response to 2-CDA, though treatment was limited by potential neurotoxicity.

Findings:

  • 2-chloro-deoxyadenosine (2-CDA) demonstrated therapeutic potential in managing Castleman disease.

Related Experiment Videos

  • The drug's efficacy was observed in both hyaline-vascular and plasma cell variants of GLNH.
  • Treatment outcomes varied, with complete remission in one case and partial response in another.

    • Implications:

    • 2-CDA represents a viable therapeutic option for patients with non-resectable Castleman disease.
    • Further research is warranted to optimize 2-CDA dosing and manage potential side effects like neurotoxicity.
    • These findings contribute to the evolving treatment landscape for atypical lymphoproliferative disorders.